Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial

Yang, WY; Dong, XL; Li, QJ; Cheng, ZF; Yuan, GY; Liu, M; Xiao, JZ; Gu, SH; Niemoeller, E; Chen, LJ; Ping, L; Souhami, E

Yang, WY (通讯作者)，China Japan Friendship Hosp, 2 Yinghuayuan E St, Beijing 100029, Peoples R China.

DIABETES OBESITY & METABOLISM, 2022; 24 (8): 1522

Abstract

Aims To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索